Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn's and Colitis Congress®

Data demonstrate that MTX-201 binds CD8 Treg, selectively eliminates pathogenic CD4 T cells, and may decrease inflammation and reduce epithelial cell damage in IBD

SEATTLE, Feb. 6, 2025 /PRNewswire/ -- Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation of new preclinical data for MTX-201, a bispecific antibody that antagonizes inhibitory KIR and promotes ICOS co-stimulation on CD8 Treg. The data will be presented during the Crohn's and Colitis Congress, February 6–8 in San Francisco, California. 

The presentation findings highlight that MTX-201:

• Selectively binds and activates CD8 Treg; does not activate cells that express only one target, including other ICOS-expressing immune cells
• Extends survival and decreases disease score in a murine model of acute GvHD
• Does not inhibit immune responses to common viral and microbial pathogens
• Reduces gut epithelial cell death and improves epithelial cell health in organoids derived from Crohn's patients' tissues

"We are encouraged by these promising results shown in patient-derived tissues and are eager to share our work with leading scientific and clinical experts at the Crohn's and Colitis Congress," said Courtney Crane, Ph.D., Senior Vice President of Translational Medicine at Mozart Therapeutics. "This presentation marks a significant step forward in the development of our second program, which aims to provide patients with a potentially durable solution for highly inflammatory autoimmune diseases like IBD."

Presentation Details:

The poster can be accessed from the Mozart Therapeutics website following the February 7 presentation.

About MTX-201
Inhibitory killer immunoglobulin-like receptors (KIR) are autoimmune checkpoints expressed on CD8 regulatory T cells, restricting their function of killing pathogenic T cells. In highly inflammatory autoimmune disease, the inducible T cell costimulator (ICOS) is upregulated on activated CD8 Treg and critical to CD8 Treg function.
MTX-201 is an antigen-agnostic bispecific antibody targeting dysfunctional CD8 Treg. The molecule aims to restore CD8 Treg function through inhibition of KIR, while promoting ICOS-mediated CD8 Treg activation, in chronic and highly inflammatory autoimmune disease.

About Mozart Therapeutics
Mozart Therapeutics is focused on developing first-in-class disease-modifying therapies for autoimmune diseases, utilizing a novel approach to restore immune system function by targeting the CD8 T regulatory network. The company is headquartered in Seattle, WA. For more information, visit www.mozart–tx.com and follow the company on LinkedIn @Mozart-tx.com. 

SOURCE Mozart Therapeutics